Published in Nat Rev Microbiol on October 26, 2009
An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis. Nature (2010) 10.37
Predictive value of interferon-γ release assays for incident active tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis (2011) 5.34
The challenge of new drug discovery for tuberculosis. Nature (2011) 4.23
Use of whole genome sequencing to estimate the mutation rate of Mycobacterium tuberculosis during latent infection. Nat Genet (2011) 4.19
Out-of-Africa migration and Neolithic coexpansion of Mycobacterium tuberculosis with modern humans. Nat Genet (2013) 3.89
Host-directed therapy of tuberculosis based on interleukin-1 and type I interferon crosstalk. Nature (2014) 3.60
Advances in the development of new tuberculosis drugs and treatment regimens. Nat Rev Drug Discov (2013) 3.50
Drug tolerance in replicating mycobacteria mediated by a macrophage-induced efflux mechanism. Cell (2011) 3.42
Tuberculosis: what we don't know can, and does, hurt us. Science (2010) 3.29
A blood RNA signature for tuberculosis disease risk: a prospective cohort study. Lancet (2016) 3.16
Understanding latent tuberculosis: a moving target. J Immunol (2010) 2.95
Vaccines against tuberculosis: where are we and where do we need to go? PLoS Pathog (2012) 2.87
Tuberculosis in antiretroviral treatment services in resource-limited settings: addressing the challenges of screening and diagnosis. J Infect Dis (2011) 2.72
Targeting bacterial membrane function: an underexploited mechanism for treating persistent infections. Nat Rev Microbiol (2011) 2.68
Interferon-γ release assays for active pulmonary tuberculosis diagnosis in adults in low- and middle-income countries: systematic review and meta-analysis. J Infect Dis (2011) 2.59
Gamma interferon release assays for detection of Mycobacterium tuberculosis infection. Clin Microbiol Rev (2014) 2.43
Type I interferon suppresses type II interferon-triggered human anti-mycobacterial responses. Science (2013) 2.34
Community-wide isoniazid preventive therapy drives drug-resistant tuberculosis: a model-based analysis. Sci Transl Med (2013) 2.28
Evasion of innate immunity by Mycobacterium tuberculosis: is death an exit strategy? Nat Rev Microbiol (2010) 2.17
A Functional Role for Antibodies in Tuberculosis. Cell (2016) 2.17
Mycobacterium tuberculosis: success through dormancy. FEMS Microbiol Rev (2012) 2.07
Functional capacity of Mycobacterium tuberculosis-specific T cell responses in humans is associated with mycobacterial load. J Immunol (2011) 2.07
Mycobacterium tuberculosis uses host triacylglycerol to accumulate lipid droplets and acquires a dormancy-like phenotype in lipid-loaded macrophages. PLoS Pathog (2011) 1.99
Sterilization of granulomas is common in active and latent tuberculosis despite within-host variability in bacterial killing. Nat Med (2013) 1.91
Sequence-based analysis uncovers an abundance of non-coding RNA in the total transcriptome of Mycobacterium tuberculosis. PLoS Pathog (2011) 1.83
Eicosanoid pathways regulate adaptive immunity to Mycobacterium tuberculosis. Nat Immunol (2010) 1.81
Host-pathogen coevolution in human tuberculosis. Philos Trans R Soc Lond B Biol Sci (2012) 1.72
Incipient and subclinical tuberculosis: defining early disease states in the context of host immune response. J Infect Dis (2011) 1.66
Targeting persisters for tuberculosis control. Antimicrob Agents Chemother (2012) 1.65
Characterization and transcriptome analysis of Mycobacterium tuberculosis persisters. MBio (2011) 1.64
Mitigating amphibian disease: strategies to maintain wild populations and control chytridiomycosis. Front Zool (2011) 1.62
Depletion of antibiotic targets has widely varying effects on growth. Proc Natl Acad Sci U S A (2011) 1.54
Pharmacokinetic evaluation of the penetration of antituberculosis agents in rabbit pulmonary lesions. Antimicrob Agents Chemother (2011) 1.50
Genome-wide mapping of transcriptional start sites defines an extensive leaderless transcriptome in Mycobacterium tuberculosis. Cell Rep (2013) 1.48
Metronidazole prevents reactivation of latent Mycobacterium tuberculosis infection in macaques. Proc Natl Acad Sci U S A (2012) 1.48
Systematic Survey of Serine Hydrolase Activity in Mycobacterium tuberculosis Defines Changes Associated with Persistence. Cell Chem Biol (2016) 1.47
Fumarate reductase activity maintains an energized membrane in anaerobic Mycobacterium tuberculosis. PLoS Pathog (2011) 1.45
Heterogeneity in tuberculosis pathology, microenvironments and therapeutic responses. Immunol Rev (2015) 1.45
Persisters, persistent infections and the Yin-Yang model. Emerg Microbes Infect (2014) 1.44
Human and Murine Clonal CD8+ T Cell Expansions Arise during Tuberculosis Because of TCR Selection. PLoS Pathog (2015) 1.44
Multifunctional essentiality of succinate metabolism in adaptation to hypoxia in Mycobacterium tuberculosis. Proc Natl Acad Sci U S A (2013) 1.41
The diagnosis of brain tuberculoma by (1)H-magnetic resonance spectroscopy. Eur J Pediatr (2011) 1.39
Intracellular growth of Mycobacterium tuberculosis after macrophage cell death leads to serial killing of host cells. Elife (2017) 1.39
In search of a new paradigm for protective immunity to TB. Nat Rev Microbiol (2014) 1.39
A genetic strategy to identify targets for the development of drugs that prevent bacterial persistence. Proc Natl Acad Sci U S A (2013) 1.39
Evaluation of the prognostic value of IFN-gamma release assay and tuberculin skin test in household contacts of infectious tuberculosis cases in Senegal. PLoS One (2010) 1.37
Latent tuberculosis: what the host "sees"? Immunol Res (2011) 1.35
Exit from dormancy in microbial organisms. Nat Rev Microbiol (2010) 1.35
Virulence of Mycobacterium tuberculosis depends on lipoamide dehydrogenase, a member of three multienzyme complexes. Cell Host Microbe (2011) 1.34
Spectrum of latent tuberculosis - existing tests cannot resolve the underlying phenotypes. Nat Rev Microbiol (2010) 1.32
Multiscale computational modeling reveals a critical role for TNF-α receptor 1 dynamics in tuberculosis granuloma formation. J Immunol (2011) 1.32
Redox homeostasis in mycobacteria: the key to tuberculosis control? Expert Rev Mol Med (2011) 1.32
Streptomycin-starved Mycobacterium tuberculosis 18b, a drug discovery tool for latent tuberculosis. Antimicrob Agents Chemother (2012) 1.31
Is passive diagnosis enough? The impact of subclinical disease on diagnostic strategies for tuberculosis. Am J Respir Crit Care Med (2012) 1.31
Unstressing intemperate models: how cold stress undermines mouse modeling. J Exp Med (2012) 1.30
Pathogenesis, immunology, and diagnosis of latent Mycobacterium tuberculosis infection. Clin Dev Immunol (2010) 1.29
Evaluating the sensitivity of Mycobacterium tuberculosis to biotin deprivation using regulated gene expression. PLoS Pathog (2011) 1.29
Natural infection of guinea pigs exposed to patients with highly drug-resistant tuberculosis. Tuberculosis (Edinb) (2011) 1.28
Pathology of post primary tuberculosis of the lung: an illustrated critical review. Tuberculosis (Edinb) (2011) 1.25
Comparative miRNA expression profiles in individuals with latent and active tuberculosis. PLoS One (2011) 1.25
Changing concepts of "latent tuberculosis infection" in patients living with HIV infection. Clin Dev Immunol (2010) 1.25
A medicinal chemists' guide to the unique difficulties of lead optimization for tuberculosis. Bioorg Med Chem Lett (2013) 1.25
Multiple toxin-antitoxin systems in Mycobacterium tuberculosis. Toxins (Basel) (2014) 1.24
Understanding latent tuberculosis: the key to improved diagnostic and novel treatment strategies. Drug Discov Today (2011) 1.21
Variability in tuberculosis granuloma T cell responses exists, but a balance of pro- and anti-inflammatory cytokines is associated with sterilization. PLoS Pathog (2015) 1.21
Tuberculosis immunopathology: the neglected role of extracellular matrix destruction. Sci Transl Med (2011) 1.19
Distinct effector memory CD4+ T cell signatures in latent Mycobacterium tuberculosis infection, BCG vaccination and clinically resolved tuberculosis. PLoS One (2012) 1.19
Cationic antimicrobial polymers and their assemblies. Int J Mol Sci (2013) 1.16
Structural and biochemical characterization of Mycobacterium tuberculosis CYP142: evidence for multiple cholesterol 27-hydroxylase activities in a human pathogen. J Biol Chem (2010) 1.16
The granuloma in tuberculosis: dynamics of a host-pathogen collusion. Front Immunol (2013) 1.15
Non-coding RNA and its potential role in Mycobacterium tuberculosis pathogenesis. RNA Biol (2012) 1.15
Chronic pulmonary cavitary tuberculosis in rabbits: a failed host immune response. Open Biol (2011) 1.14
Interferon release does not add discriminatory value to smear-negative HIV-tuberculosis algorithms. Eur Respir J (2011) 1.13
Data needs for evidence-based decisions: a tuberculosis modeler's 'wish list'. Int J Tuberc Lung Dis (2013) 1.12
Bovine tuberculosis: the genetic basis of host susceptibility. Proc Biol Sci (2010) 1.12
The ongoing challenge of latent tuberculosis. Philos Trans R Soc Lond B Biol Sci (2014) 1.12
Nitrate respiration protects hypoxic Mycobacterium tuberculosis against acid- and reactive nitrogen species stresses. PLoS One (2010) 1.11
Development of new vaccines and drugs for TB: limitations and potential strategic errors. Future Microbiol (2011) 1.10
Exosomes isolated from mycobacteria-infected mice or cultured macrophages can recruit and activate immune cells in vitro and in vivo. J Immunol (2012) 1.09
A hybrid multi-compartment model of granuloma formation and T cell priming in tuberculosis. J Theor Biol (2011) 1.08
Early Changes by (18)Fluorodeoxyglucose positron emission tomography coregistered with computed tomography predict outcome after Mycobacterium tuberculosis infection in cynomolgus macaques. Infect Immun (2014) 1.08
Borrelia burgdorferi, the Causative Agent of Lyme Disease, Forms Drug-Tolerant Persister Cells. Antimicrob Agents Chemother (2015) 1.08
Mycobacterium marinum causes a latent infection that can be reactivated by gamma irradiation in adult zebrafish. PLoS Pathog (2012) 1.07
Differential risk of tuberculosis reactivation among anti-TNF therapies is due to drug binding kinetics and permeability. J Immunol (2012) 1.07
Point-of-care assays for tuberculosis: role of nanotechnology/microfluidics. Biotechnol Adv (2013) 1.06
Latent tuberculosis infection: myths, models, and molecular mechanisms. Microbiol Mol Biol Rev (2014) 1.06
Novel inhibitors of cholesterol degradation in Mycobacterium tuberculosis reveal how the bacterium's metabolism is constrained by the intracellular environment. PLoS Pathog (2015) 1.06
Activities of TMC207, rifampin, and pyrazinamide against Mycobacterium tuberculosis infection in guinea pigs. Antimicrob Agents Chemother (2010) 1.05
Methylcitrate cycle defines the bactericidal essentiality of isocitrate lyase for survival of Mycobacterium tuberculosis on fatty acids. Proc Natl Acad Sci U S A (2014) 1.05
Low-dose exposure of C57BL/6 mice to burkholderia pseudomallei mimics chronic human melioidosis. Am J Pathol (2011) 1.05
Human lung immunity against Mycobacterium tuberculosis: insights into pathogenesis and protection. Am J Respir Crit Care Med (2010) 1.03
Immunology studies in non-human primate models of tuberculosis. Immunol Rev (2015) 1.03
Higher human CD4 T cell response to novel Mycobacterium tuberculosis latency associated antigens Rv2660 and Rv2659 in latent infection compared with tuberculosis disease. Vaccine (2010) 1.03
The epidemiology of Mycobacterium bovis in wild deer and feral pigs and their roles in the establishment and spread of bovine tuberculosis in New Zealand wildlife. N Z Vet J (2015) 1.02
Within the Enemy's Camp: contribution of the granuloma to the dissemination, persistence and transmission of Mycobacterium tuberculosis. Front Immunol (2013) 1.02
Mycobacterium tuberculosis responds to chloride and pH as synergistic cues to the immune status of its host cell. PLoS Pathog (2013) 1.01
Immunodiagnosis of tuberculosis: a dynamic view of biomarker discovery. Clin Microbiol Rev (2011) 1.01
Inactivation of fructose-1,6-bisphosphate aldolase prevents optimal co-catabolism of glycolytic and gluconeogenic carbon substrates in Mycobacterium tuberculosis. PLoS Pathog (2014) 1.01
Methylated HBHA produced in M. smegmatis discriminates between active and non-active tuberculosis disease among RD1-responders. PLoS One (2011) 1.01
Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med (2001) 18.25
Genes required for mycobacterial growth defined by high density mutagenesis. Mol Microbiol (2003) 16.82
Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat Rev Drug Discov (2006) 15.21
A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science (2004) 13.04
A common mechanism of cellular death induced by bactericidal antibiotics. Cell (2007) 12.92
Persistence of Mycobacterium tuberculosis in macrophages and mice requires the glyoxylate shunt enzyme isocitrate lyase. Nature (2000) 11.48
Transcriptional Adaptation of Mycobacterium tuberculosis within Macrophages: Insights into the Phagosomal Environment. J Exp Med (2003) 10.67
Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. Ann Intern Med (2008) 9.49
Genetic requirements for mycobacterial survival during infection. Proc Natl Acad Sci U S A (2003) 9.15
Inhibition of respiration by nitric oxide induces a Mycobacterium tuberculosis dormancy program. J Exp Med (2003) 7.99
Tuberculous granulomas are hypoxic in guinea pigs, rabbits, and nonhuman primates. Infect Immun (2008) 4.93
The transcriptional responses of Mycobacterium tuberculosis to inhibitors of metabolism: novel insights into drug mechanisms of action. J Biol Chem (2004) 4.75
PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release. Science (2008) 4.74
ideR, An essential gene in mycobacterium tuberculosis: role of IdeR in iron-dependent gene expression, iron metabolism, and oxidative stress response. Infect Immun (2002) 4.54
Mistranslation of membrane proteins and two-component system activation trigger antibiotic-mediated cell death. Cell (2008) 4.47
High rates of clinical and subclinical tuberculosis among HIV-infected ambulatory subjects in Tanzania. Clin Infect Dis (2005) 4.45
Experimental Mycobacterium tuberculosis infection of cynomolgus macaques closely resembles the various manifestations of human M. tuberculosis infection. Infect Immun (2003) 4.16
Biomarkers for tuberculosis disease activity, cure, and relapse. Lancet Infect Dis (2009) 4.14
Dynamic antigen-specific T-cell responses after point-source exposure to Mycobacterium tuberculosis. Am J Respir Crit Care Med (2006) 3.98
Identification of a nitroimidazo-oxazine-specific protein involved in PA-824 resistance in Mycobacterium tuberculosis. Proc Natl Acad Sci U S A (2005) 3.97
Metronidazole is bactericidal to dormant cells of Mycobacterium tuberculosis. Antimicrob Agents Chemother (1994) 3.92
The enduring hypoxic response of Mycobacterium tuberculosis. PLoS One (2008) 3.87
Tuberculosis morbidity in a controlled trial of the prophylactic use of isoniazid among household contacts. Am Rev Respir Dis (1962) 3.82
Progression of chronic pulmonary tuberculosis in mice aerogenically infected with virulent Mycobacterium tuberculosis. Tuber Lung Dis (1997) 3.55
How soon after infection with HIV does the risk of tuberculosis start to increase? A retrospective cohort study in South African gold miners. J Infect Dis (2004) 3.50
Microarray analysis of the Mycobacterium tuberculosis transcriptional response to the acidic conditions found in phagosomes. J Bacteriol (2002) 3.35
Differential expression of iron-, carbon-, and oxygen-responsive mycobacterial genes in the lungs of chronically infected mice and tuberculosis patients. Proc Natl Acad Sci U S A (2003) 3.14
Mycobacterium tuberculosis invasion of macrophages: linking bacterial gene expression to environmental cues. Cell Host Microbe (2007) 3.01
Cytological and transcript analyses reveal fat and lazy persister-like bacilli in tuberculous sputum. PLoS Med (2008) 3.01
The protonmotive force is required for maintaining ATP homeostasis and viability of hypoxic, nonreplicating Mycobacterium tuberculosis. Proc Natl Acad Sci U S A (2008) 2.92
In vivo gene silencing identifies the Mycobacterium tuberculosis proteasome as essential for the bacteria to persist in mice. Nat Med (2007) 2.76
Microbial phenotypic heterogeneity and antibiotic tolerance. Curr Opin Microbiol (2007) 2.70
Early events in Mycobacterium tuberculosis infection in cynomolgus macaques. Infect Immun (2006) 2.63
Pulmonary tuberculoma evaluated by means of FDG PET: findings in 10 cases. Radiology (2000) 2.55
Single-cell microbiology: tools, technologies, and applications. Microbiol Mol Biol Rev (2004) 2.53
Eliminating latent tuberculosis. Trends Microbiol (2009) 2.47
Role of the methylcitrate cycle in Mycobacterium tuberculosis metabolism, intracellular growth, and virulence. Mol Microbiol (2006) 2.39
Unique transcriptome signature of Mycobacterium tuberculosis in pulmonary tuberculosis. Infect Immun (2006) 2.27
Isoniazid prophylaxis among Alaskan Eskimos: a final report of the bethel isoniazid studies. Am Rev Respir Dis (1979) 2.15
Effect of treatment of latent tuberculosis infection on the T cell response to Mycobacterium tuberculosis antigens. J Infect Dis (2005) 2.07
Eliminating human tuberculosis in the twenty-first century. J R Soc Interface (2008) 2.00
GSMN-TB: a web-based genome-scale network model of Mycobacterium tuberculosis metabolism. Genome Biol (2007) 1.99
Target deconvolution strategies in drug discovery. Nat Rev Drug Discov (2007) 1.94
Probing host pathogen cross-talk by transcriptional profiling of both Mycobacterium tuberculosis and infected human dendritic cells and macrophages. PLoS One (2008) 1.91
In situ detection of Mycobacterium tuberculosis transcripts in human lung granulomas reveals differential gene expression in necrotic lesions. Infect Immun (2002) 1.88
Disruption of response regulator gene, devR, leads to attenuation in virulence of Mycobacterium tuberculosis. FEMS Microbiol Lett (2004) 1.86
A CONTROLLED TRIAL OF ISONIAZID PROPHYLAXIS IN MENTAL INSTITUTIONS. Am Rev Respir Dis (1963) 1.80
The treated pulmonary lesion and its tubercle bacillus. II. The death and resurrection. Am J Med Sci (1956) 1.70
Synergy between individual TNF-dependent functions determines granuloma performance for controlling Mycobacterium tuberculosis infection. J Immunol (2009) 1.66
Role of the dosR-dosS two-component regulatory system in Mycobacterium tuberculosis virulence in three animal models. Infect Immun (2008) 1.63
Biosynthesis and recycling of nicotinamide cofactors in mycobacterium tuberculosis. An essential role for NAD in nonreplicating bacilli. J Biol Chem (2008) 1.62
Multi-targeting by monotherapeutic antibacterials. Nat Rev Drug Discov (2007) 1.60
Differential antibiotic susceptibilities of starved Mycobacterium tuberculosis isolates. Antimicrob Agents Chemother (2005) 1.55
Flux balance analysis of mycolic acid pathway: targets for anti-tubercular drugs. PLoS Comput Biol (2005) 1.55
Contribution of CD8+ T cells to control of Mycobacterium tuberculosis infection. J Immunol (2006) 1.49
The aerosol rabbit model of TB latency, reactivation and immune reconstitution inflammatory syndrome. Tuberculosis (Edinb) (2007) 1.49
Bactericidal action of ofloxacin, sulbactam-ampicillin, rifampin, and isoniazid on logarithmic- and stationary-phase cultures of Mycobacterium tuberculosis. Antimicrob Agents Chemother (1996) 1.48
Management of health care workers after inadvertent exposure to tuberculosis: a guide for the use of preventive therapy. Ann Intern Med (1995) 1.46
Isoniazid prophylaxis differently modulates T-cell responses to RD1-epitopes in contacts recently exposed to Mycobacterium tuberculosis: a pilot study. Respir Res (2007) 1.45
Improved tetracycline repressors for gene silencing in mycobacteria. Nucleic Acids Res (2009) 1.41
Mycobacterial bacilli are metabolically active during chronic tuberculosis in murine lungs: insights from genome-wide transcriptional profiling. J Bacteriol (2007) 1.40
Fragment-based approaches to enzyme inhibition. Curr Opin Biotechnol (2007) 1.37
Uptake rates of 18F-fluorodeoxyglucose and 11C-choline in lung cancer and pulmonary tuberculosis: a positron emission tomography study. Chest (2003) 1.32
Intense uptake of [F-18]-fluoro-2 deoxy-D-glucose in active pulmonary tuberculosis. Ann Nucl Med (2003) 1.32
Principles of antibiotic penetration into abscess fluid. Pharmacology (2006) 1.30
Differences in reactivation of tuberculosis induced from anti-TNF treatments are based on bioavailability in granulomatous tissue. PLoS Comput Biol (2007) 1.29
Interferon-gamma responses after isoniazid chemotherapy for latent tuberculosis. Respirology (2008) 1.26
Antibiotic abscess penetration: fosfomycin levels measured in pus and simulated concentration-time profiles. Antimicrob Agents Chemother (2005) 1.22
Bactericidal action of gatifloxacin, rifampin, and isoniazid on logarithmic- and stationary-phase cultures of Mycobacterium tuberculosis. Antimicrob Agents Chemother (2005) 1.21
Evaluation of therapeutic response of tuberculoma using F-18 FDG positron emission tomography. Clin Nucl Med (2008) 1.17
The relA homolog of Mycobacterium smegmatis affects cell appearance, viability, and gene expression. J Bacteriol (2005) 1.16
Long term isoniazid prophylaxis. Controlled trial on INH prophylaxis after recent tuberculin conversion in young adults. Bull Int Union Tuberc (1968) 1.10
The targets of currently used antibacterial agents: lessons for drug discovery. Curr Pharm Des (2007) 1.05
Multigenic control of tuberculosis resistance: analysis of a QTL on mouse chromosome 7 and its synergism with sst1. Genes Immun (2008) 0.97
Direct comparison of low-dose and Cornell-like models of chronic and reactivation tuberculosis in genetically susceptible I/St and resistant B6 mice. Tuberculosis (Edinb) (2004) 0.96
Tuberculosis genes expressed during persistence and reactivation in the resistant rabbit model. Tuberculosis (Edinb) (2008) 0.95
[Rifomycin levels in the lung and tuberculous lesions in man]. Acta Tuberc Pneumol Belg (1969) 0.94
[Rifampicin and isoniazid concentration in the blood and resected lungs in tuberculosis with combined use of the preparations]. Probl Tuberk (1980) 0.90
[Comparative evaluation of rifampicin and isoniazid penetration into the pathological foci of the lungs in tuberculosis patients]. Probl Tuberk (1985) 0.90
Peptide deformylase inhibitors of Mycobacterium tuberculosis: synthesis, structural investigations, and biological results. Bioorg Med Chem Lett (2008) 0.88
Transcriptional Adaptation of Mycobacterium tuberculosis within Macrophages: Insights into the Phagosomal Environment. J Exp Med (2003) 10.67
An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis. Nature (2010) 10.37
Inhibition of respiration by nitric oxide induces a Mycobacterium tuberculosis dormancy program. J Exp Med (2003) 7.99
Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. Lancet Infect Dis (2008) 5.94
Tuberculosis. Lancet (2007) 5.45
Predictive value of interferon-γ release assays for incident active tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis (2011) 5.34
The proteasome of Mycobacterium tuberculosis is required for resistance to nitric oxide. Science (2003) 5.26
High-dose vitamin D(3) during intensive-phase antimicrobial treatment of pulmonary tuberculosis: a double-blind randomised controlled trial. Lancet (2011) 4.73
A single dose of vitamin D enhances immunity to mycobacteria. Am J Respir Crit Care Med (2007) 4.07
Controlling gene expression in mycobacteria with anhydrotetracycline and Tet repressor. Nucleic Acids Res (2005) 4.00
Identification of a nitroimidazo-oxazine-specific protein involved in PA-824 resistance in Mycobacterium tuberculosis. Proc Natl Acad Sci U S A (2005) 3.97
The immune response in tuberculosis. Annu Rev Immunol (2013) 3.91
Out-of-Africa migration and Neolithic coexpansion of Mycobacterium tuberculosis with modern humans. Nat Genet (2013) 3.89
Meropenem-clavulanate is effective against extensively drug-resistant Mycobacterium tuberculosis. Science (2009) 3.73
Characterization and management of paradoxical upgrading reactions in HIV-uninfected patients with lymph node tuberculosis. Clin Infect Dis (2005) 3.35
Distinct, specific IL-17- and IL-22-producing CD4+ T cell subsets contribute to the human anti-mycobacterial immune response. J Immunol (2008) 3.19
A membrane protein preserves intrabacterial pH in intraphagosomal Mycobacterium tuberculosis. Nat Med (2008) 2.97
Mycobacterium bovis BCG response regulator essential for hypoxic dormancy. J Bacteriol (2002) 2.94
The protonmotive force is required for maintaining ATP homeostasis and viability of hypoxic, nonreplicating Mycobacterium tuberculosis. Proc Natl Acad Sci U S A (2008) 2.92
Tuberculous meningitis: a uniform case definition for use in clinical research. Lancet Infect Dis (2010) 2.86
Randomized placebo-controlled trial of prednisone for paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome. AIDS (2010) 2.83
In vivo gene silencing identifies the Mycobacterium tuberculosis proteasome as essential for the bacteria to persist in mice. Nat Med (2007) 2.76
IFN-gamma- and TNF-independent vitamin D-inducible human suppression of mycobacteria: the role of cathelicidin LL-37. J Immunol (2007) 2.75
Novel relationship between tuberculosis immune reconstitution inflammatory syndrome and antitubercular drug resistance. Clin Infect Dis (2009) 2.66
Immune reconstitution and "unmasking" of tuberculosis during antiretroviral therapy. Am J Respir Crit Care Med (2008) 2.63
Gluconeogenic carbon flow of tricarboxylic acid cycle intermediates is critical for Mycobacterium tuberculosis to establish and maintain infection. Proc Natl Acad Sci U S A (2010) 2.62
A chemical genetic screen in Mycobacterium tuberculosis identifies carbon-source-dependent growth inhibitors devoid of in vivo efficacy. Nat Commun (2010) 2.49
Eliminating latent tuberculosis. Trends Microbiol (2009) 2.47
SQ109 targets MmpL3, a membrane transporter of trehalose monomycolate involved in mycolic acid donation to the cell wall core of Mycobacterium tuberculosis. Antimicrob Agents Chemother (2012) 2.41
Lack of effect of intravaginal dehydroepiandrosterone (DHEA, prasterone) on the endometrium in postmenopausal women. Menopause (2015) 2.41
Effect of HIV-1 infection on T-Cell-based and skin test detection of tuberculosis infection. Am J Respir Crit Care Med (2006) 2.40
Selective killing of nonreplicating mycobacteria. Cell Host Microbe (2008) 2.39
Neutrophil-mediated innate immune resistance to mycobacteria. J Clin Invest (2007) 2.38
Reciprocal seasonal variation in vitamin D status and tuberculosis notifications in Cape Town, South Africa. Proc Natl Acad Sci U S A (2011) 2.29
Metabolomics of Mycobacterium tuberculosis reveals compartmentalized co-catabolism of carbon substrates. Chem Biol (2010) 2.28
Clinical, immunological, and epidemiological importance of antituberculosis T cell responses in HIV-infected Africans. Clin Infect Dis (2007) 2.23
Ancestral antibiotic resistance in Mycobacterium tuberculosis. Proc Natl Acad Sci U S A (2005) 2.21
Vitamin D in the treatment of pulmonary tuberculosis. J Steroid Biochem Mol Biol (2007) 2.21
Mycobacterial survival strategies in the phagosome: defence against host stresses. Cell Microbiol (2009) 2.18
Organ specificity, colonization and clearance dynamics in vivo following oral challenges with the murine pathogen Citrobacter rodentium. Cell Microbiol (2004) 2.18
High levels of multidrug resistant tuberculosis in new and treatment-failure patients from the Revised National Tuberculosis Control Programme in an urban metropolis (Mumbai) in Western India. BMC Public Health (2009) 2.13
Diagnosis of childhood tuberculosis and host RNA expression in Africa. N Engl J Med (2014) 2.12
Recent and rapid emergence of W-Beijing strains of Mycobacterium tuberculosis in Cape Town, South Africa. Clin Infect Dis (2008) 2.11
MyD88 primes macrophages for full-scale activation by interferon-gamma yet mediates few responses to Mycobacterium tuberculosis. J Exp Med (2003) 2.10
Human macrophage responses to clinical isolates from the Mycobacterium tuberculosis complex discriminate between ancient and modern lineages. PLoS Pathog (2011) 2.07
Effect of treatment of latent tuberculosis infection on the T cell response to Mycobacterium tuberculosis antigens. J Infect Dis (2005) 2.07
Acquired predisposition to mycobacterial disease due to autoantibodies to IFN-gamma. J Clin Invest (2005) 2.06
Vitamin D accelerates resolution of inflammatory responses during tuberculosis treatment. Proc Natl Acad Sci U S A (2012) 2.05
The clinical consequences of strain diversity in Mycobacterium tuberculosis. Trans R Soc Trop Med Hyg (2008) 2.03
Hypervirulent mutant of Mycobacterium tuberculosis resulting from disruption of the mce1 operon. Proc Natl Acad Sci U S A (2003) 2.00
Immune reconstitution inflammatory syndrome in HIV-infected patients receiving antiretroviral therapy : pathogenesis, clinical manifestations and management. Drugs (2008) 1.95
Neutrophils in tuberculosis: friend or foe? Trends Immunol (2011) 1.94
Detection of tuberculosis in HIV-infected and -uninfected African adults using whole blood RNA expression signatures: a case-control study. PLoS Med (2013) 1.91
Ex vivo characterization of early secretory antigenic target 6-specific T cells at sites of active disease in pleural tuberculosis. Clin Infect Dis (2004) 1.88
Transcriptional blood signatures distinguish pulmonary tuberculosis, pulmonary sarcoidosis, pneumonias and lung cancers. PLoS One (2013) 1.86
Sequence-based analysis uncovers an abundance of non-coding RNA in the total transcriptome of Mycobacterium tuberculosis. PLoS Pathog (2011) 1.83
A glutamate-alanine-leucine (EAL) domain protein of Salmonella controls bacterial survival in mice, antioxidant defence and killing of macrophages: role of cyclic diGMP. Mol Microbiol (2005) 1.78
Transmission of Mycobacterium tuberculosis undetected by tuberculin skin testing. Am J Respir Crit Care Med (2006) 1.72
Vitamin D-binding protein directs monocyte responses to 25-hydroxy- and 1,25-dihydroxyvitamin D. J Clin Endocrinol Metab (2010) 1.72
The burden of mycobacterial disease in ethiopian cattle: implications for public health. PLoS One (2009) 1.70
Tuberculosis-associated immune reconstitution inflammatory syndrome and unmasking of tuberculosis by antiretroviral therapy. Clin Chest Med (2009) 1.68
Detectable changes in the blood transcriptome are present after two weeks of antituberculosis therapy. PLoS One (2012) 1.68
Silencing Mycobacterium smegmatis by using tetracycline repressors. J Bacteriol (2007) 1.66
The 19-kDa Mycobacterium tuberculosis protein induces macrophage apoptosis through Toll-like receptor-2. J Immunol (2003) 1.66
A deletion defining a common Asian lineage of Mycobacterium tuberculosis associates with immune subversion. Proc Natl Acad Sci U S A (2006) 1.64
High-sensitivity MALDI-MRM-MS imaging of moxifloxacin distribution in tuberculosis-infected rabbit lungs and granulomatous lesions. Anal Chem (2011) 1.64
Biosynthesis and recycling of nicotinamide cofactors in mycobacterium tuberculosis. An essential role for NAD in nonreplicating bacilli. J Biol Chem (2008) 1.62
Neurologic manifestations of paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome: a case series. Clin Infect Dis (2009) 1.62
High prevalence and increased severity of pathology of bovine tuberculosis in Holsteins compared to zebu breeds under field cattle husbandry in central Ethiopia. Clin Vaccine Immunol (2007) 1.62
Nutrient-starved, non-replicating Mycobacterium tuberculosis requires respiration, ATP synthase and isocitrate lyase for maintenance of ATP homeostasis and viability. Microbiology (2009) 1.60
A high-throughput screen to identify inhibitors of ATP homeostasis in non-replicating Mycobacterium tuberculosis. ACS Chem Biol (2012) 1.59
Depletion of antibiotic targets has widely varying effects on growth. Proc Natl Acad Sci U S A (2011) 1.54
HIV-1 infection impairs the bronchoalveolar T-cell response to mycobacteria. Am J Respir Crit Care Med (2009) 1.54
Pharmacokinetic evaluation of the penetration of antituberculosis agents in rabbit pulmonary lesions. Antimicrob Agents Chemother (2011) 1.50
Acid resistance in Mycobacterium tuberculosis. J Bacteriol (2009) 1.48
The immunological aspects of latency in tuberculosis. Clin Immunol (2004) 1.48
Comprehensive analysis of methods used for the evaluation of compounds against Mycobacterium tuberculosis. Tuberculosis (Edinb) (2012) 1.47
Acid-susceptible mutants of Mycobacterium tuberculosis share hypersusceptibility to cell wall and oxidative stress and to the host environment. J Bacteriol (2008) 1.46
Sensitive profiling of chemically diverse bioactive lipids. J Lipid Res (2007) 1.45
Fumarate reductase activity maintains an energized membrane in anaerobic Mycobacterium tuberculosis. PLoS Pathog (2011) 1.45
Induction of ER stress in macrophages of tuberculosis granulomas. PLoS One (2010) 1.45
Heterogeneity in tuberculosis pathology, microenvironments and therapeutic responses. Immunol Rev (2015) 1.45
Para-aminosalicylic acid acts as an alternative substrate of folate metabolism in Mycobacterium tuberculosis. Science (2012) 1.44
Clinical deterioration during antitubercular treatment at a district hospital in South Africa: the importance of drug resistance and AIDS defining illnesses. PLoS One (2009) 1.43
Mycobacterial nonhomologous end joining mediates mutagenic repair of chromosomal double-strand DNA breaks. J Bacteriol (2007) 1.42
Antitubercular nucleosides that inhibit siderophore biosynthesis: SAR of the glycosyl domain. J Med Chem (2006) 1.41
Improved tetracycline repressors for gene silencing in mycobacteria. Nucleic Acids Res (2009) 1.41
Inhibition of siderophore biosynthesis in Mycobacterium tuberculosis with nucleoside bisubstrate analogues: structure-activity relationships of the nucleobase domain of 5'-O-[N-(salicyl)sulfamoyl]adenosine. J Med Chem (2008) 1.40
Protection from Alzheimer's-like disease in the mouse by genetic ablation of inducible nitric oxide synthase. J Exp Med (2005) 1.40